Thalidomide in 42 patients with prurigo nodularis hyde

Dermatology

Volumn 223, Issue 2, 2011, Pages 107-112

  Andersen, Tina P ^a   Fogh, Karsten ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Peripheral neuropathy; Prurigo nodularis Hyde; Thalidomide

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; STEROID; THALIDOMIDE;

DEPRESSION; DIARRHEA; DIZZINESS; DRUG WITHDRAWAL; FACE EDEMA; FACIAL NERVE PARALYSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMPOTENCE; MALAISE; NAUSEA; NERVOUSNESS; PERIPHERAL NEUROPATHY; PHOTOTHERAPY; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PRURIGO NODULARIS HYDE; RASH; RAYNAUD PHENOMENON; RESTLESS LEGS SYNDROME; RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; SKIN DISEASE; THROMBOCYTHEMIA; TREATMENT DURATION; TREMOR; ULTRAVIOLET RADIATION; WEIGHT GAIN;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; PRURIGO; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 82455210418     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000331577     Document Type: Review

References (17)

1. Rosenbach M, Werth VP: Dermatologic therapeutics: thalidomide. A practical guide. Dermatol Ther 2007; 20: 175-186. (Pubitemid 350029308)
2. Somers GF: Pharmacological properties of thalidomide ( α -phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960; 15: 111-116.
3. Sharma NL, Sharma VC, Mahajan VK, et al: Thalidomide: An experience in therapeutic outcome and adverse reactions. J Dermatolog Treat 2007; 18: 335-340. (Pubitemid 350223205)
4. Tseng S, Pak G, Washenik K, et al: Rediscovering thalidomide: A review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996; 35: 969-979. (Pubitemid 26422122)
5. Cavaletti G, Beronio A, Reni L, et al: Thalidomide sensory neurotoxicity. A clinical and neurophysiologic study. Neurology 2004; 62: 2291-2293. (Pubitemid 38787791)
6. Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G: Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002; 1: 412-413. (Pubitemid 34246272)
7. Bastuji-Garin S, Ochonsky S, Bouche P, Gheradi RK, Duguet C, Djerradine Z, Poli F, Revuz J: Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002; 119: 1020-1026. (Pubitemid 35430479)
8. Doherty SD, Hsu S: A case series of 48 patients treated with thalidomide. J Drugs Dermatol 2008; 7: 769-773.
9. Faver IR, Guerra SG, Su WPD, El-Azhary R: Thalidomide for dermatology: a review of clinical uses and adverse effects. Int J Dermatol 2005; 44: 61-67. (Pubitemid 40201995)
10. Radomsky CL, Levine N: Thalidomide. Dermatol Clin 2001; 19: 87-103. (Pubitemid 32038048)
11. Moraes M, Russo G: Thalidomide and its dermatologic uses. Am J Med Sci 2001; 321: 321-326. (Pubitemid 32428832)
12. Wines NY, Cooper AJ, Wines MP: Thalidomide in dermatology. Australas J Dermatol 2002; 43: 229-238.
13. Nasca MR, Micali G, Cheigh NH, West LE, West DP: Dermatologic and nondermatologic uses of thalidomide. Ann Pharmacother 2003; 37: 1307-1320. (Pubitemid 37040224)
14. Laffitte E, Revuz J: Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf 2004; 3: 47-56. (Pubitemid 38765186)
15. Paghdal KV, Schwartz R: Thalidomide and its dermatologic uses. Acta Dermatovenerol Croat 2007; 15: 39-44. (Pubitemid 46649172)
16. Chen M, Doherty SD, Hsu S: Innovative uses of thalidomide. Dermatol Clin 2010; 28: 577-586.
17. Wolkenstein P, Latarjet J, Roujeau JC, et al: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589. (Pubitemid 28515243)